Screener
Zevra Therapeutics, Inc. ZVRA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | (4,486) | (3,433) | (8,878) | (6,691) |
| Selling, general and administrative | (16,559) | (20,782) | (37,342) | (40,327) |
| Total operating expenses | (21,045) | (24,215) | (46,220) | (47,018) |
| Income (loss) from operations | 16,777 | (71,039) | 68,923 | (76,401) |
| Other (expense) income: | ||||
| Gain on sale of PRV | — | 148,325 | — | 148,325 |
| Loss on extinguishment of debt | — | — | (2,756) | — |
| Loss on derivative liability | — | — | (7,216) | — |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s operating income?
- Zevra Therapeutics, Inc. (ZVRA) reported operating income of $16.78M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s operating income changed year-over-year?
- Zevra Therapeutics, Inc.'s operating income increased by 123.6% year-over-year, from -$71.04M to $16.78M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s operating income?
- Over 2 years (2022 to 2024), Zevra Therapeutics, Inc.'s operating income has grown at a 43.0% compound annual growth rate (CAGR), from -$42.57M to -$87M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Zevra Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude